Sensitive skin management

U.S.6489286 (2002) Lukenbach et al. (Johnson Johnson) Nonionic/amphoteric/anionic surfactants at least two conditioning agents selected from cationic celluloses, sugar derivatives, and homopolymers or copolymers Nonirritating, suitable for children and adults having sensitive skin and eyes imparts wet and dry detangling, and manageability... 

At the same time, several types of data necessary to ensure proper management of occupational risks associated with a drug substance are not generally useful in evaluating potential patient risks. So the necessary tests—eye and skin irritation, sensitization and inhalation toxicity, as well as assessment of the hazards of byproducts and impurities that do not get incorporated into the final therapeutic product—are not performed in the normal course of development. 

Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol. 2000 1 361-368. 

Workers are potentially exposed to a variety of substances during daily industrial operations. The OSHA estimates that a large segment of workers are simultaneously exposed to more than one substance and suffer from adverse effects. Adverse effects include many acute and chronic diseases (e.g., allergic sensitization, cancer, cardiovascular diseases, dermatitis, erythema, edema, irritation of the mucous membrane, irritation of the skin, kidney disease, liver disease, metabolic interferences, narcosis, neuropathy, ocular effects, odor effects, respiratory diseases, systemic toxicity). These should be properly addressed by concerned management and the individual worker to improve chemical safety. Workers come in contact directly or indirectly during different work conditions hence it is important to understand the possible adverse effects that these chemicals may cause vis-a-vis chemical safety. 

However, hazard identification alone does very little to protect human health—it is only the start of the process. When a chemical has been identified as a potential skin sensitizer, then unless it is banned from use, the risk that it presents must be assessed and managed. To achieve this, it is vital to characterize the relative potency of the identified sensitizer, not least since the currently available evidence indicates that this may vary over perhaps five orders of magnitude [25, 26]. As mentioned earlier, this has been successfully achieved using the LLNA EC3 value [27-34], Consequently, various workers have begun to compare the predictions from in vitro methods to this potency measure (e.g., [82, 85]). It would be preferable though to develop predictive systems in vitro which deliver information on the relative potency of skin sensitizers in humans rather than in mice. To this end, a... 

---